The Technical Analyst
APx Acquisition Corp. I [APXI]
Exchange: NASDAQ Sector: Financial Services Industry: Shell Companies
APx Acquisition Corp. I Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $11.45
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 113.47 mill |
| EPS: | 0.400 |
| P/E: | 28.62 |
| Earnings Date: | Mar 30, 2023 |
| SharesOutstanding: | 9.91 mill |
| Avg Daily Volume: | 0.0150 mill |
| RATING 2024-04-19 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 28.62 | sector: PE -18.15 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 28.62 | industry: PE -25.74 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 11.44 - 11.46 ( +/- 0.09%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-21 | Bransfield Kyle P | Sell | 800 000 | Class A ordinary shares |
| 2024-03-21 | Bransfield Kyle P | Buy | 800 000 | Class A ordinary shares |
| 2023-10-02 | Bransfield Kyle P | Buy | 3 342 188 | Class A ordinary shares |
| 2023-10-02 | Bransfield Kyle P | Sell | 3 342 188 | Class B ordinary shares |
| 2023-09-08 | Bransfield Kyle P | Buy | 3 342 188 | Class B ordinary shares |
| INSIDER POWER |
|---|
| -23.16 |
| Last 9 transactions |
| Buy: 5 112 500 | Sell: 8 494 688 |
Forecast:
11:46 - $11.45
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $11.45 (0.00% ) |
| Volume | 0.0014 mill |
| Avg. Vol. | 0.0150 mill |
| % of Avg. Vol | 9.03 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APXI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
APXI
APx Acquisition Corp. I. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Mexico City, Mexico.
Last 10 Buy Signals
Latest Press Releases
2024-03-26 08:25:00 - Press Release
Apx Acquisition Corp. I, Omnigenicsai Corp And Multiplai Health Ltd Enter Into Business Combination Agreement To Create A Global Ai-driven Genomics Platform
Nashville, tenn. , march 26, 2024 /prnewswire/ -- apx acquisition corp. i (nasdaq: apxi) ("apx"), a publicly traded special purpose acquisition company, omnigenicsai corp ("omnigenicsai"), a precision medicine company incubated by bioceres group plc, and multiplai health ltd ("multiplai"), a uk-based ai-enabled preventive medicine company, have entered into a definitive business combination agreement ("bca") that, upon closing, would result in omnigenicsai becoming a publicly listed company.
2023-12-28 09:06:00 - Press Release
Apx Acquisition Corp. I Receives Nasdaq Notice On Late Filing Of Its Form 10-q
Nashville, tenn., dec. 28, 2023 /prnewswire/ -- apx acquisition corp. i (nasdaq: apxi) ("company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "letter") on december 21, 2023 from the listing qualifications department of the nasdaq stock market ("nasdaq").
2023-12-01 21:43:00 - Press Release
Apx Acquisition Corp. I & Bioceres Group Announce Letter Of Intent For A Business Combination With A Precision Medicine Diagnostic And Wellness Services Company
Nashville, tenn. , dec. 1, 2023 /prnewswire/ -- apx acquisition corp. i (nasdaq: apxi) ("company"), a publicly traded special purpose acquisition company, announced today that it has signed a non-binding letter of intent ("loi") for a proposed business combination (the "business combination") with a precision medicine company that offers genomic diagnostic tests in clinical genomics, oncology, human microbiome and reproductive genomics, as well as a digital nutrition-based dna and gut microbiome wellness service that promotes wellbeing and prevents disease ("target"), that would result in a public listing of the combined company upon completion of the proposed business combination.